Last reviewed · How we verify
FKB238 (bevacizumab)
FKB238 is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells.
FKB238 is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells. Used for Metastatic colorectal cancer, Metastatic non-small cell lung cancer, Metastatic breast cancer.
At a glance
| Generic name | FKB238 (bevacizumab) |
|---|---|
| Sponsor | Centus Biotherapeutics Limited |
| Drug class | VEGF inhibitor (monoclonal antibody) |
| Target | VEGF (Vascular Endothelial Growth Factor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Bevacizumab is a monoclonal antibody that binds to circulating VEGF, preventing its interaction with VEGF receptors on endothelial cells. By neutralizing VEGF, the drug inhibits new blood vessel formation (angiogenesis) that tumors require for growth and metastasis. This starves tumors of oxygen and nutrients, slowing or halting their progression.
Approved indications
- Metastatic colorectal cancer
- Metastatic non-small cell lung cancer
- Metastatic breast cancer
- Renal cell carcinoma
- Glioblastoma
Common side effects
- Hypertension
- Proteinuria
- Bleeding/hemorrhage
- Thromboembolic events
- Gastrointestinal perforation
- Wound healing complications
- Fatigue
Key clinical trials
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PHASE2, PHASE3)
- Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer (PHASE3)
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (PHASE3)
- A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer (PHASE2)
- Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study (PHASE3)
- Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer (PHASE1)
- Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FKB238 (bevacizumab) CI brief — competitive landscape report
- FKB238 (bevacizumab) updates RSS · CI watch RSS
- Centus Biotherapeutics Limited portfolio CI